BAP enters the mid-June trading week defined by a sharp divergence at the top of the Street: Morgan Stanley upgraded the stock to Overweight and raised its target from $375 to $480 on June 17, while JPMorgan stepped the other way, cutting to Neutral just two days earlier.
The Morgan Stanley move is the most consequential analyst action on Credicorp in months, and the timing matters. Jorge Kuri's upgrade lands after BAP has already gained 15% in a month, closing at $364.28. The $480 target implies a further 32% from current levels — a bold call on a stock that has already re-rated sharply. JPMorgan's same-week downgrade to Neutral, at an unchanged $415 target, tells the opposite story: the risk/reward is less attractive after the run. UBS and HSBC remain constructive with Buy ratings, and the consensus sits at hold across six analysts — a split picture that reflects genuine disagreement rather than a lazy midpoint. The mean target of $386 looks modest given the Morgan Stanley raise, but that will take time to filter through. EPS surprise ranks in the 98th percentile of the ORTEX universe — Credicorp has a strong habit of beating estimates — and near-term earnings momentum scores rank in the 87th percentile on a 30-day basis. The PE has expanded to 11.7x and price-to-book to 2.3x, both up roughly 17% over the past month, meaning investors are now paying meaningfully more for the same franchise.
The lending market tells a story that is conspicuously relaxed for a stock moving this fast. Availability is extraordinarily loose — roughly 3,363% of short interest, meaning there are more than thirty shares available to borrow for every one already shorted. That reading, while down from above 9,999% in early May, is still well into what would be considered an abundant supply environment. Cost to borrow has ticked up about 13% on the week to 0.49%, but at that level it remains firmly in "low" territory. Short interest itself has fallen nearly 8% over the past week to around 1.34 million shares. The borrow market is offering no signal that bearish conviction is building — if anything, shorts have been retreating as the price has climbed.
Options positioning has moved noticeably more defensive in recent weeks. The put/call ratio of 0.95 runs well above its 20-day average of 0.59, a gap of roughly 1.2 standard deviations. That shift began around June 8 and has held, suggesting some participants are hedging their exposure into the move rather than chasing further upside. The context is important: with the next earnings event not until August 13, the hedging is not event-driven in the immediate term. It looks more like caution from holders sitting on a 15% monthly gain, protecting positions rather than pressing them.
The ownership picture adds useful texture. Capital Research added over 2.1 million shares in the most recent period, lifting its stake to 5.5% of the company — one of the largest single additions among the top holders. Baillie Gifford added 1.3 million shares and JP Morgan Asset Management added 600,000. BlackRock added 706,000. That cluster of institutional accumulation from well-regarded long-only managers provides a demand backdrop that supports the price action and somewhat reconciles the Morgan Stanley upgrade with what has already happened to the stock. Insider activity, by contrast, skews the other way: a subsidiary CEO sold $1.1 million in early June, and the CFO sold $362,000 in late May. Neither sale is large relative to the stock's market footprint, but net 90-day insider activity is modestly negative in value terms.
Earnings history shows BAP can move sharply in either direction around results. The May print triggered a 7.3% one-day drop, though the stock recovered to post a 2% gain over the following week. The March print produced a 6.8% one-day gain. With the August 13 event still eight weeks out, that volatility pattern is less immediately relevant — but it is worth carrying into any position assessment. What to watch next is whether the Morgan Stanley upgrade catalyses a fresh wave of institutional buying that pushes the stock toward the $415–$480 target cluster, or whether JPMorgan's more cautious read — that the valuation expansion has already done the heavy lifting — proves the more durable call after a month that has already re-rated Credicorp by 15%.
See the live data behind this article on ORTEX.
Open BAP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
